639 results on '"Wirth, Lori J."'
Search Results
102. Impact of baseline tumor burden on overall survival in patients with radioiodine‐refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial
103. American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment
104. Thyroid – Medullary
105. Decreased EBNA-1-Specific CD8+ T Cells in Patients with Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma
106. Efficacy and Toxicity of Chemoradiotherapy Using Intensity-Modulated Radiotherapy for Unknown Primary of Head and Neck
107. Cell‐free human papillomavirus DNA kinetics after surgery for human papillomavirus–associated oropharyngeal cancer
108. Cell-Free HPV DNA Provides an Accurate and Rapid Diagnosis of HPV-Associated Head and Neck Cancer
109. Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial
110. Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion–Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 Trial
111. Lenvatinib in Radioiodine-Refractory Thyroid Cancer
112. Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
113. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve -mutant medullary thyroid cancer.
114. Intraductal carcinoma of the salivary gland with NCOA4-RET: expanding the morphologic spectrum and an algorithmic diagnostic approach
115. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer
116. SY33-2 New perspectives on the treatment of thyroid cancer: novel drugs for medullary thyroid cancer
117. O10-3 Selpercatinib (LOXO-292) in patients (pts) with RET-altered thyroid cancer
118. Abstract CT165: A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma
119. Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy
120. Hu et al. Supplemental Tables.docx
121. Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments
122. Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma
123. Selpercatinib efficacy and safety in patients with RET-altered thyroid cancer: A clinical trial update.
124. NTRK, RET, BRAF, and ALK fusions in thyroid fine-needle aspirates (FNAs).
125. Efficacy of selpercatinib after prior systemic therapy in patients with RET mutant medullary thyroid cancer.
126. Patient-reported outcomes (PROs) from a phase II trial of pembrolizumab for HPV-associated papilloma patients with laryngeal, tracheal and/or pulmonary involvement.
127. Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules
128. Advanced Thyroid Carcinoma: Evolving Systemic Therapy Options
129. Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib
130. Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer
131. Motesanib diphosphate in differentiated thyroid cancer
132. PD-1 Blockade in Anaplastic Thyroid Carcinoma
133. A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
134. Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization
135. Case 5–2013: A 52-Year-Old Woman with a Mass in the Thyroid
136. Does Current Training in Radiation Oncology Prepare Radiation Oncologists to Optimally Manage Patients With Head and Neck Cancer?
137. Case 29-2012: A 49-Year-Old Man with Pain and Cranial-Nerve Palsies after Treatment of Oral Cancer
138. Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma
139. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
140. PD-1 Blockade in Anaplastic Thyroid Carcinoma
141. The Afirma Xpression Atlas for thyroid nodules and thyroid cancer metastases: Insights to inform clinical decision‐making from a fine‐needle aspiration sample
142. Immune functional portraits of head and neck cancer using next generation sequencing.
143. Lenvatinib plus pembrolizumab combination therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC): Results of a multicenter phase II international thyroid oncology group trial.
144. Immune checkpoint inhibitor in nasopharyngeal carcinoma: Multi-institution experience.
145. Selpercatinib (LOXO-292) in patients with RET-mutant medullary thyroid cancer.
146. Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment
147. OR28-04 Identification of Novel and Rare Receptor Tyrosine Kinase Fusions in Thyroid Fine Needle Aspirates
148. MON-521 An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib (LEN) for the Treatment of Anaplastic Thyroid Cancer (ATC)
149. SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation
150. MON-LB88 Positive Predictive Value of TP53 Variants in Bethesda III/IV Thyroid Fine-Needle Aspirates
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.